Patents by Inventor Vinay Bhaskar

Vinay Bhaskar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220205466
    Abstract: The present disclosure relates to a mechanical actuator having a modified locking mechanism and fewer components. The actuator has a cylinder, a locking recess formed on an interior wall of the cylinder, and a piston assembly that moves between an extended position and a retracted position responsive to fluid pressure within the cylinder. A lock is connected to the piston assembly and moves radially between a locked position and an unlocked position responsive to the fluid pressure within the cylinder.
    Type: Application
    Filed: October 14, 2021
    Publication date: June 30, 2022
    Inventors: Bhuvan Bhaskar, Jagdish L. Shinde, Vinay Sreedhar, Prashantha K. Ana, Kiritharan Gurusamy
  • Patent number: 11352403
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: June 7, 2022
    Assignee: Werewolf Therapeutics, Inc.
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • Patent number: 11261247
    Abstract: Antibodies that modulate insulin receptor signaling are provided.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: March 1, 2022
    Assignee: XOMA (US) LLC
    Inventors: John Corbin, Mark Leslie White, Susan R. Watson, Vinay Bhaskar
  • Publication number: 20220056096
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Application
    Filed: November 10, 2021
    Publication date: February 24, 2022
    Inventors: William WINSTON, Daniel HICKLIN, Vinay BHASKAR, Luke EVNIN, Patrick BAEUERLE, Jose Andres SALMERON GARCIA, Heather BRODKIN, Cynthia SEIDEL-DUGAN
  • Publication number: 20210403524
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Application
    Filed: May 14, 2021
    Publication date: December 30, 2021
    Inventors: William WINSTON, Daniel HICKLIN, Vinay BHASKAR, Luke EVNIN, Patrick BAEUERLE, Jose Andres SALMERON GARCIA, Heather BRODKIN, Cynthia SEIDEL-DUGAN
  • Publication number: 20210115102
    Abstract: Provided herein are separation moieties that are suitable for use in conjunction with a variety of therapeutic payloads. The separation moieties serve to generate conditionally active macromolecules whereby the macromolecules have reduced or minimal biological activity until the separation moieties are modified under specific conditions.
    Type: Application
    Filed: October 28, 2020
    Publication date: April 22, 2021
    Inventors: William WINSTON, Luke EVNIN, Vinay BHASKAR, Giselle KNUDSEN, Daniel HICKLIN, Cynthia SEIDEL-DUGAN, Jose Andres SALMERON GARCIA, Heather BRODKIN
  • Publication number: 20200283490
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Application
    Filed: May 21, 2020
    Publication date: September 10, 2020
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • Publication number: 20200283489
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-12. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Application
    Filed: May 21, 2020
    Publication date: September 10, 2020
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • Publication number: 20200231696
    Abstract: Provided in this disclosure are anti-CD38 binding domains, a composition comprising the anti-CD38 binding domains, nucleic acids encoding the anti-CD38 binding domains, and a method of using the anti-CD38 binding domains or the composition for treating multiple myeloma.
    Type: Application
    Filed: January 23, 2020
    Publication date: July 23, 2020
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Vinay Bhaskar, Erin Willert
  • Patent number: 10696724
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: June 30, 2020
    Assignee: Werewolf Therapeutics, Inc.
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • Patent number: 10696723
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-12. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: June 30, 2020
    Assignee: Werewolf Therapeutics, Inc.
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • Publication number: 20200202051
    Abstract: The present invention relates to a method for predicting outcome of a process used for manufacturing a sample in a bioreactor, the process belonging to a category. The method comprises selecting (51) a process model based on the category; accessing (53) historic data related to past process runs for manufacturing the sample; accessing (53) current data obtained (54) from a current process run of the process. The obtained current data, which is based on the selected process model, comprises: process strategy data, bioreactor instrument data, data from online sensors and/or data from offline sensors. The method further comprises predicting (62) an outcome of at least one selected parameter of the current process run for manufacturing the sample based on the accessed historic data and current data. The present invention also relates to a method for modelling a process and a control system (10) for controlling a process.
    Type: Application
    Filed: June 18, 2018
    Publication date: June 25, 2020
    Inventors: Krishna Kumar Swaminathan, Sridhar Dasaratha, Sittal George, Vinay Bhaskar Jammu, Alok Singh Chauhan, Nagaraju Konduru, Neelima Boddapati, Ankita Bhatia, Mithilesh Mohanty, Harsha Aeron, Andreas Castan
  • Publication number: 20200040105
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Application
    Filed: October 17, 2019
    Publication date: February 6, 2020
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • Publication number: 20200040052
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Application
    Filed: June 11, 2019
    Publication date: February 6, 2020
    Inventors: William WINSTON, Daniel HICKLIN, Vinay BHASKAR, Luke EVNIN, Patrick BAEUERLE, Jose Andres SALMERON GARCIA, Heather BRODKIN
  • Publication number: 20200031951
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Application
    Filed: May 14, 2019
    Publication date: January 30, 2020
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • Publication number: 20190367576
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-12. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Application
    Filed: June 11, 2019
    Publication date: December 5, 2019
    Inventors: William WINSTON, Daniel HICKLIN, Vinay BHASKAR, Luke EVNIN, Patrick BAEUERLE, Jose Andres SALMERON GARCIA, Heather BRODKIN
  • Patent number: 10494444
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: December 3, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • Patent number: 10336833
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: July 2, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • Patent number: 10260388
    Abstract: A system includes one or more processors and a resonant sensor that contacts oil within an engine of a vehicle system. The sensor generates electrical stimuli at different times during an operational life of the engine. Each electrical stimulus has multiple different frequencies applied to the oil. The one or more processors receive electrical signals representing impedance responses of the oil to the electrical stimuli. The one or more processors determine a concentration of a polar analyte in the oil at the different times based on the impedance responses and calculate a degradation value for the engine based on the polar analyte concentration. Responsive to the degradation value exceeding a designated degradation threshold, the one or more processors at least one of schedule maintenance for the vehicle system, provide an alert to schedule maintenance for the vehicle system, or prohibit operation of the vehicle system until maintenance is performed.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: April 16, 2019
    Assignee: General Electric Company
    Inventors: Radislav Alexandrovich Potyrailo, Rahul Srinivas Prabhu, Vinay Bhaskar Jammu, Venkatesh Madyastha
  • Publication number: 20180371081
    Abstract: Antibodies that modulate insulin receptor signaling are provided.
    Type: Application
    Filed: March 14, 2018
    Publication date: December 27, 2018
    Inventors: John A. Corbin, Mark Leslie White, Susan R. Watson, Vinay Bhaskar